| Indication | Stiff Person Syndrome |
| Drug | mivocabtagene autoleucel |
| Mechanism of Action | CAR T cell therapy |
| Company | Kyverna Therapeutics |
| Trial Phase | Phase 2 |
| Category | Regulatory Milestone |
| Sub Category | Regulatory Submission Filed |
| Therapeutic Area | Rare Diseases & Genetics |
| Regulatory Agency | FDA |
| Patient Population Size | 6,000 patients in the U.S. |
| Regulatory Filing Type | Biologics License Application (BLA) |
| Regulatory Filing Timeline | by the end of the year (BLA submission), first half of 2026 (potential approval) |
| Other Indications Under Investigation | generalized myasthenia gravis, progressive multiple sclerosis |
| Licensing Date | January 2022 |
| Licensing Partner | National Institutes of Health (NIH) |
| Conference | American Academy of Neurology‘s annual meeting (AAN 2026) |
Kyverna Poised for First Autoimmune CAR T Filing with Miv-cel
Kyverna Therapeutics is poised to become the first company to achieve a regulatory filing for a CAR T cell therapy in an autoimmune disease. The company plans to submit a biologics license application (BLA) for mivocabtagene autoleucel (miv-cel) to the FDA by the end of the year, targeting stiff person syndrome (SPS). If approved, potentially in the first half of 2026, miv-cel would address a significant unmet need for the estimated 6,000 U.S. patients with SPS, a rare disorder currently lacking specific treatments. In a registrational Phase 2 trial, miv-cel demonstrated impressive mobility benefits, enabling two-thirds of patients using mobility aids at baseline to walk without them after treatment.
- Kyverna Therapeutics is on the verge of submitting the first-ever biologics license application (BLA) for a CAR T cell therapy, mivocabtagene autoleucel (miv-cel), for an autoimmune disease. The initial target indication is stiff person syndrome (SPS), a rare disorder affecting approximately 6,000 patients in the U.S. for which there are no specific approved treatments, often leading to disability.
- The registrational Phase 2 clinical trial for miv-cel in stiff person syndrome demonstrated significant and transformative clinical efficacy. A key outcome highlighted was that two-thirds of patients who relied on a mobility aid at the beginning of the study were able to ambulate independently after receiving the one-time miv-cel treatment, indicating a substantial improvement in their quality of life and functional mobility.
- Miv-cel is envisioned as a 'pipeline-in-a-product' for Kyverna, with many patients from the Phase 2 trial showing sustained strong results two years post-treatment, suggesting durable benefits. The company is also advancing miv-cel into additional trials for other neuroimmunology diseases, including generalized myasthenia gravis and progressive multiple sclerosis, where early data have shown improvements in disability and fatigue.
Addressing the Significant Unmet Need in Stiff Person Syndrome
Despite an increasing understanding of its autoimmune underpinnings, significant unmet needs persist in Stiff Person Syndrome (SPS), a rare and disabling neurological disorder. Key challenges span the entire patient journey, from initial presentation and diagnosis through long-term management and end-of-life care. Current research and clinical focus highlight several critical gaps and patient populations requiring specialized attention.
Diagnostic Delays and Misdiagnosis: Diagnostic challenges remain a primary unmet need. The rarity of SPS, coupled with a lack of standardized diagnostic criteria and significant phenotypic polymorphism, frequently leads to diagnostic delays. The condition can mimic other disorders, such as psychogenic movement disorders or narcolepsy, further complicating timely and accurate diagnosis, which is essential for initiating aggressive immunotherapy early.
Limited and Unsustainable Treatment Options: The development of effective, durable treatments is a crucial gap. While immunomodulatory therapies like therapeutic plasma exchange (TPE) can provide immediate symptom improvement in refractory cases, the effects are often not sustainable. This highlights the need for novel therapeutic strategies that offer long-term disease control and symptom management.
Management of Complex Comorbidities: Patients with SPS often present with complex medical profiles that require integrated, multidisciplinary management. A key area of focus is the co-occurrence of psychiatric conditions, including anxiety, agoraphobia, depression, and psychosis, which are poorly understood in this population. Similarly, patients with multiple autoimmune comorbidities require comprehensive care strategies that address all facets of their health.
Challenges in End-of-Life Care: Providing hospice care for SPS patients presents a significant challenge. Effective symptom-modifying treatments, such as intravenous immunoglobulin (IVIG) and intrathecal baclofen, often fall outside standard hospice formularies. This necessitates the development of flexible, patient-centered, and interdisciplinary approaches to ensure adequate symptom palliation and prevent hospital readmissions during end-of-life care.
Underrecognized Physical Complications: Atraumatic and recurrent fractures are an underrecognized complication of SPS. Uncontrolled muscle spasms can lead to bone fractures and failure of surgical fracture fixations, complicating management. This underscores the need for proactive medical optimization of patients with immunotherapies and anti-spasmodics before undertaking surgical interventions to reduce the risk of complications.
Frequently Asked Questions
References
- [1] Crane PD, Sillau S et al.. Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System. Neurology. 2024 Dec 24. 39621949
- [2] Dorr A, DiVittorio A et al.. Stiff Person Syndrome: A Case Report. Cureus. 2025 Dec. 41552052
- [3] Jean M, Paidi R et al.. Complexities in Managing Psychosis in a Patient With Stiff-Person Syndrome: A Case Report. Cureus. 2024 Jan. 38406022
- [4] Goncharova ZA, Markova EA. [The difficulties with diagnostics of the stiff man syndrome]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2024. 39575966
- [5] Maarad N, Rahmani M et al.. Stiff Person Syndrome With Positive Anti-glutamic Acid Decarboxylase (GAD) Autoantibodies. Cureus. 2024 Aug. 39193054
- [6] Matsui N, Tanaka K et al.. [Stiff-Person Syndrome: Results of the First Nationwide Survey in Japan]. Brain and nerve = Shinkei kenkyu no shinpo. 2024 Aug. 39117597
- [7] Narula K, Singh Curry V et al.. Stiff person syndrome and type 1 diabetes in pregnancy. Obstetric medicine. 2025 Oct 8. 41081287
- [8] Riveros D, Buyukkurt A et al.. Understanding stiff-person syndrome: Epidemiological trends, diagnostic challenges, and treatment advances. Journal of neuroimmunology. 2026 Jun. 41793840
- [9] Çelik EB, Tuncer A. Comparing the Efficacy of Manual Therapy and Exercise to Synchronized Telerehabilitation with Self-Manual Therapy and Exercise in Treating Subacromial Pain Syndrome: A Randomized Controlled Trial. Healthcare (Basel, Switzerland). 2024 May 24. 38891149
- [10] Sørensen HT, Sørensen TT et al.. Occurrence and Mortality of Stiff Person Syndrome in Denmark. Neuroepidemiology. 2026 Jun 8. 42258595
- [11] Burholt V, Wiles J et al.. Understanding the contribution of primary and community services to health system resilience during the COVID19 Pandemic in Aotearoa, New Zealand: a qualitative interview study. BMC health services research. 2024 Dec 24. 39719555
- [12] Svendsen M, Layton BP et al.. Stiff Person Syndrome in the Hospice Patient: A Case Report and Discussion. Journal of palliative medicine. 2026 Mar 11. 41081611
- [13] Park SH, Song SH et al.. Machine learning characterization of a rare neurologic disease via electronic health records: a proof-of-principle study on stiff person syndrome. BMC neurology. 2024 Aug 3. 39097681
- [14] Fakhari MS, Poorsaadat L et al.. Stiff-person syndrome revealing an occult gray zone lymphoma: A diagnostic challenge. Clinical case reports. 2023 Dec. 38098799
- [15] Torabi N, Reddy P et al.. Recurrent Tachycardia, Abdominal, and Chest Pain as a Presentation of Stiff Person Syndrome. Case reports in medicine. 2025. 40786935
- [16] Kumawat V, Tripathi PP et al.. Therapeutic role of plasma exchange in the management of stiff person syndrome: experience from a tertiary care centre. Hematology, transfusion and cell therapy. 2024 Oct-Dec. 38614933
- [17] Steele KR, Upton E et al.. Intensive 7-day internet-delivered cognitive behaviour therapy for social anxiety disorder: study protocol for a randomised controlled trial. Trials. 2025 Apr 18. 40251626
- [18] Jain RS, Pemawat A et al.. Expanding the Understanding of Stiff-Person Syndrome: Insights from 17 Cases in India. Annals of Indian Academy of Neurology. 2024 Jul 1. 39150463
- [19] Roy S, Huang Y et al.. Core diagnostic features of stiff person syndrome: insights from a case-control study. Journal of neurology. 2025 May 5. 40323494
- [20] Ebrahimpour A, Biglari F et al.. Atraumatic hip fracture due to stiff person syndrome: Case report and literature review. International journal of surgery case reports. 2024 Sep. 39126929
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
